Table 3

Comparison of HOMA2-%β and HOMA2-%S before and after selenium supplementation

Placebo (n=188)Selenium (n=201)Total (n=389)P value
HOMA2-%β
Baseline % beta cell function
 Mean (SD)95.5 (29.6)97.6 (32.0)96.6 (30.9)0.51*
 Median (Q1, Q3)94.0 (77.0, 112.5)91.9 (76.9, 112.4)92.6 (77.0, 112.4)
Post % beta cell function
 Mean (SD)98.6 (37.2)100.6 (34.0)99.6 (35.6)0.57
 Median (Q1, Q3)92.0 (76.3, 113.0)93.8 (78.0, 114.2)92.4 (76.9, 113.3)
∆ % beta cell function
 Mean (SD)3.1 (29.8)3.1 (24.0)3.1 (26.9)0.99
 Median (Q1, Q3)−0.2 (-11.0, 10.5)1.5 (-11.1, 13.7)0.4 (-11.0, 12.4)
HOMA2-%S
Baseline % insulin sensitivity
 Mean (SD)251.9 (423.1)241.5 (316.2)246.5 (371.3)1.0†
 Median (Q1, Q3)140.8 (87.1, 289.1)146.9 (77.4, 284.5)144.3 (83.5, 284.9)
Post % insulin sensitivity
 Mean (SD)332.8 (1603.3)241.0 (393.2)285.4 (1149.2)0.52
 Median (Q1, Q3)131.3 (74.0, 270.4)136.1 (79.4, 284.4)133.9 (79.0, 282.1)
∆ Insulin sensitivity
 Mean (SD)80.9 (1530.9)−0.5 (223.2)38.9 (1075.6)0.40
 Median (Q1, Q3)−9.3 (-56.7, 31.4)−2.3 (-53.9, 43.5)−6.1 (-54.1, 34.2)
  • *Student’s t-test.

  • †Kruskal-Wallis test.

  • HOMA2-%β, homeostatic model assessment of β-cell function; HOMA2-%S, homeostatic model assessment of insulin sensitivity.